Langdon S - Search Results

1

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.

Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, Gourley C, Faratian D. Palmieri C, et al. Among authors: langdon s. Br J Cancer. 2013 May 28;108(10):2039-44. doi: 10.1038/bjc.2013.199. Epub 2013 May 7. Br J Cancer. 2013. PMID: 23652306 Free PMC article.

2

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams AR, Lessells AM, Macleod KG, Smyth JF, Miller WR. Bartlett JM, et al. Among authors: langdon sp. Br J Cancer. 1996 Feb;73(3):301-6. doi: 10.1038/bjc.1996.53. Br J Cancer. 1996. PMID: 8562334 Free PMC article.

3

Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours.

Wilson KE, Langdon SP, Lessells AM, Miller WR. Wilson KE, et al. Among authors: langdon sp. Br J Cancer. 1996 Oct;74(7):999-1004. doi: 10.1038/bjc.1996.480. Br J Cancer. 1996. PMID: 8855965 Free PMC article.

4

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

McPhillips F, Mullen P, Monia BP, Ritchie AA, Dorr FA, Smyth JF, Langdon SP. McPhillips F, et al. Among authors: langdon sp. Br J Cancer. 2001 Nov 30;85(11):1753-8. doi: 10.1054/bjoc.2001.2139. Br J Cancer. 2001. PMID: 11742498 Free PMC article.

5

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. Macleod K, et al. Among authors: langdon sp. Cancer Res. 2005 Aug 1;65(15):6789-800. doi: 10.1158/0008-5472.CAN-04-2684. Cancer Res. 2005. PMID: 16061661

6

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.

Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR, Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H, Langdon SP. Smyth JF, et al. Clin Cancer Res. 2007 Jun 15;13(12):3617-22. doi: 10.1158/1078-0432.CCR-06-2878. Clin Cancer Res. 2007. PMID: 17575226 Free article. Clinical Trial.

7

Hormone therapy for epithelial ovarian cancer.

Langdon SP, Smyth JF. Langdon SP, et al. Curr Opin Oncol. 2008 Sep;20(5):548-53. doi: 10.1097/CCO.0b013e3283063912. Curr Opin Oncol. 2008. PMID: 19106659 Review.

8

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, Kay C, Um IH, Langdon S, Goryanin I, Harrison DJ. Faratian D, et al. Among authors: langdon s. Cancer Res. 2009 Aug 15;69(16):6713-20. doi: 10.1158/0008-5472.CAN-09-0777. Epub 2009 Jul 28. Cancer Res. 2009. PMID: 19638581

9

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP. Nagumo Y, et al. Mol Cancer Res. 2009 Sep;7(9):1563-71. doi: 10.1158/1541-7786.MCR-09-0101. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737968

10

How can systems pathology help us personalize cancer therapy?

Faratian D, Langdon SP, Harrison DJ. Faratian D, et al. Discov Med. 2009 Aug;8(41):81-6. Discov Med. 2009. PMID: 19788873 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters